|
Author, year | Fluid compared | N | Operation | Conclusion |
|
Primary outcome: renal function (serum Cr, GFR, neutrophil gelatinase-associated lipocalin, urine albumin, and cystatin C) |
Mahmood [33], 2007 | 6% HES 200/0.62 (Elohes) 6% HES 130/0.4 (Voluven) 4% gelatin (Gelofusine) | 62 | Abdominal aortic aneurysm repair | Less derangement in marker of glomerular filtration and tubular function in both HES groups No difference in AKI or RRT |
Mukhtar [38], 2009 | 5% human albumin 6% HES 130/0.4 (Voluven) | 40 | Living donor liver transplant | No difference in serum Cr, CrCl, or cystatin C level No difference in AKI or RRT |
Demir [20], 2015 | 6% HES 130/0.4 (Voluven) 4% gelatin (Gelofusine) | 36 | Living donor liver transplant | Significantly decreased GFR in gelatin group No difference in AKI or RRT |
Kancir [27], 2015 | 6% HES 130/0.4 (Voluven) NSS | 36 | Prostatectomy | No significant difference in renal impairment by U-NGAL, P-NGAL, and serum Cr |
Kammerer [26], 2018 | 5% human albumin 6% HES 130/0.4 (Voluven) | 100 | Cystectomy | No significant difference in renal impairment by cystatin C ratio, P-NGAL, and GFR |
|
Primary outcome was another objective but also had these outcomes |
Rittoo [47], 2005 | 6% HES 200/0.62 (Elohes) 4% gelatin (Gelofusine) | 40 | Abdominal aortic aneurysm repair | Less derangement in marker of glomerular function in HES group |
Ando [18], 2008 | Acetate Ringer HES 70/0.5 (Hespander) | 20 | Major abdominal surgery | No difference in glomerular function (urine Albumin/ Cr ratio), GFR |
Feldheiser [15], 2013 | Jonosteril 6% HES130/0.4 (Volulyte) | 48 | Cytoreductive surgery | No significant renal function impairment (P-NGAL and Cr) |
Yates [16], 2014 | Hartmann’s solution 6% HES130/0.4 (Volulyte) | 202 | Colorectal surgery | No significant renal function impairment |
Joosten [17], 2018 | Plasmalyte 6% HES130/0.4 (Volulyte) | 160 | Major abdominal surgery | No significant renal function impairment or RRT |
|